Details of the Drug Combination

General Information of Drug Combination (ID: DCN603S)

Drug Combination Name
Taxol SNX-2112
Indication
Disease Entry Status REF
Ovarian endometrioid adenocarcinoma Investigative [1]
Component Drugs Taxol   DMUOT9V SNX-2112   DMB5A80
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL
High-throughput Screening Result Testing Cell Line: A2780
Zero Interaction Potency (ZIP) Score: 2.4
Bliss Independence Score: 2.06
Loewe Additivity Score: 1.28
LHighest Single Agent (HSA) Score: 5.05

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Taxol
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Approved [2]
Solid tumour/cancer 2A00-2F9Z Approved [3]
Pancreatic cancer 2C10 Phase 3 [4]
Gastric adenocarcinoma 2B72 Phase 2 [5]
Ovarian cancer 2C73 Phase 2 [5]
Taxol Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Apoptosis regulator Bcl-2 (BCL-2) TTJGNVC BCL2_HUMAN Modulator [2]
Tubulin beta (TUBB) TTYFKSZ NOUNIPROTAC Modulator [2]
------------------------------------------------------------------------------------
Indication(s) of SNX-2112
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [6]
SNX-2112 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Heat shock protein 90 alpha (HSP90A) TT78R5H HS90A_HUMAN Inhibitor [6]
------------------------------------------------------------------------------------
SNX-2112 Interacts with 14 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Inhibitor of nuclear factor kappa-B kinase subunit alpha (CHUK) OTLF4ZB1 IKKA_HUMAN Decreases Expression [7]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Cleavage [7]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Decreases Expression [7]
Endoplasmic reticulum chaperone BiP (HSPA5) OTFUIRAO BIP_HUMAN Decreases Expression [7]
Endoplasmin (HSP90B1) OT02XLBR ENPL_HUMAN Decreases Expression [7]
RAC-alpha serine/threonine-protein kinase (AKT1) OT8H2YY7 AKT1_HUMAN Decreases Expression [7]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Increases Expression [7]
Caspase-9 (CASP9) OTD4RFFG CASP9_HUMAN Increases Expression [7]
Cytochrome c (CYCS) OTBFALJD CYC_HUMAN Affects Localization [7]
Transcription factor p65 (RELA) OTUJP9CN TF65_HUMAN Decreases Expression [7]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Increases Expression [7]
Bcl-2-like protein 1 (BCL2L1) OTRC5K9O B2CL1_HUMAN Decreases Expression [7]
Heat shock protein 75 kDa, mitochondrial (TRAP1) OTNG0L8J TRAP1_HUMAN Decreases Expression [7]
Caspase-8 (CASP8) OTA8TVI8 CASP8_HUMAN Increases Activity [7]
------------------------------------------------------------------------------------
⏷ Show the Full List of 14 DOT(s)

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Ewing sarcoma-peripheral primitive neuroectodermal tumour DCR57AE ES2 Investigative [8]
Breast and ovarian cancer syndrome DCNZ06C UWB1289+BRCA1 Investigative [9]
Breast carcinoma DCG6GFK OCUBM Investigative [9]
Carcinoma DCF49E1 OV90 Investigative [9]
Carcinoma DCS4BSH MDAMB436 Investigative [9]
Colon adenocarcinoma DC9L7NX LOVO Investigative [9]
Colon carcinoma DCRIXV0 RKO Investigative [9]
Rectal adenocarcinoma DCQZ3RL SW837 Investigative [9]
Adenocarcinoma DCO160B COLO320DM Investigative [1]
Adenocarcinoma DCBAQG3 SW-620 Investigative [1]
Amelanotic melanoma DCAKJ2B A2058 Investigative [1]
Germ cell tumour DCXRNYU PA1 Investigative [1]
Large cell lung carcinoma DCWVYYX NCI-H460 Investigative [1]
Malignant melanoma DC7F7VA A375 Investigative [1]
Malignant melanoma DC0QXK4 HT144 Investigative [1]
Malignant melanoma DCDRR2F RPMI7951 Investigative [1]
Malignant melanoma DCJX4O1 SKMEL30 Investigative [1]
Malignant melanoma DC80HQW UACC62 Investigative [1]
Mesothelioma DCPXR49 MSTO Investigative [1]
Non small cell carcinoma DCM1MOO SKMES1 Investigative [1]
Ovarian serous cystadenocarcinoma DCKN6S7 SK-OV-3 Investigative [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 21 DrugCom(s)

References

1 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2 Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res. 2009 Sep 1;69(17):6906-14.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 Heat shock protein 90: inhibitors in clinical trials. J Med Chem. 2010 Jan 14;53(1):3-17.
7 The Hsp90 inhibitor SNX-2112, induces apoptosis in multidrug resistant K562/ADR cells through suppression of Akt/NF-B and disruption of mitochondria-dependent pathways. Chem Biol Interact. 2013 Sep 5;205(1):1-10. doi: 10.1016/j.cbi.2013.06.007. Epub 2013 Jun 15.
8 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
9 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.